Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Dyne Therapeutics, Inc. (DYN) since 2020 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Dyne Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1818794.
Total stock buying since 2020: $93,286,579.
Total stock sales since 2020: $220,256,609.
Total stock option exercises since 2020: $7,682,728.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 100,000 | $911,000 | 13,652 | $165,477 | 0 | $0 |
| 2024 | 1,746,285 | $31,050,547 | 7,344,916 | $211,138,148 | 1,475,761 | $7,131,559 |
| 2023 | 0 | $0 | 479,710 | $5,994,262 | 328,030 | $334,869 |
| 2022 | 1,869,162 | $20,000,032 | 221,888 | $2,732,346 | 210,000 | $216,300 |
| 2021 | 0 | $0 | 14,037 | $226,376 | 0 | $0 |
| 2020 | 2,175,000 | $41,325,000 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-07 | 100,000 | $911,000 | 0 | $0 | 0 | $0 |
| 2025-03 | 0 | $0 | 11,054 | $129,235 | 0 | $0 |
| 2025-02 | 0 | $0 | 2,598 | $36,242 | 0 | $0 |
| 2024-12 | 0 | $0 | 389,679 | $11,474,883 | 0 | $0 |
| 2024-11 | 0 | $0 | 37,014 | $1,173,675 | 16,500 | $143,385 |
| 2024-10 | 0 | $0 | 85,601 | $3,018,914 | 0 | $0 |
| 2024-09 | 32,000 | $1,050,560 | 354,382 | $12,292,660 | 116,478 | $1,221,038 |
| 2024-08 | 0 | $0 | 1,256,887 | $56,479,644 | 0 | $0 |
| 2024-06 | 0 | $0 | 174,736 | $5,619,361 | 159,950 | $886,122 |
| 2024-05 | 0 | $0 | 43,612 | $1,389,425 | 30,426 | $31,338 |
| 2024-03 | 0 | $0 | 911,239 | $24,713,722 | 735,471 | $3,915,824 |
| 2024-02 | 0 | $0 | 3,656,268 | $86,663,790 | 13,217 | $37,226 |
| 2024-01 | 1,714,285 | $29,999,987 | 435,498 | $8,312,074 | 403,719 | $896,626 |
| 2023-12 | 0 | $0 | 20,888 | $230,130 | 0 | $0 |
| 2023-11 | 0 | $0 | 9,939 | $73,548 | 0 | $0 |
| 2023-09 | 0 | $0 | 33,852 | $333,703 | 0 | $0 |
| 2023-06 | 0 | $0 | 383,777 | $4,933,599 | 318,030 | $327,569 |
| 2023-03 | 0 | $0 | 21,254 | $282,982 | 0 | $0 |
| 2023-01 | 0 | $0 | 10,000 | $140,300 | 10,000 | $7,300 |
| 2022-12 | 1,869,162 | $20,000,032 | 0 | $0 | 0 | $0 |
| 2022-10 | 0 | $0 | 210,000 | $2,629,522 | 210,000 | $216,300 |
| 2022-03 | 0 | $0 | 11,888 | $102,824 | 0 | $0 |
| 2021-09 | 0 | $0 | 14,037 | $226,376 | 0 | $0 |
| 2020-09 | 2,175,000 | $41,325,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-07-14 | Cox John (CEO & President) | Buy | 100,000 | 9.11 | 911,000 |
| 2025-03-13 | Friedl-naderer Johanna (Chief Commercial Officer) | Sale | 143 | 12.12 | 1,733 |
| 2025-03-11 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 2,153 | 11.38 | 24,501 |
| 2025-03-11 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Sale | 1,343 | 11.38 | 15,283 |
| 2025-03-05 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 1,094 | 11.83 | 12,942 |
| 2025-03-05 | Kerr Douglas (Chief Medical Officer) | Sale | 1,343 | 11.83 | 15,887 |
| 2025-03-05 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Sale | 917 | 11.83 | 10,848 |
| 2025-03-05 | Cox John (CEO & President) | Sale | 4,061 | 11.83 | 48,041 |
| 2025-02-18 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 2,598 | 13.95 | 36,242 |
| 2024-12-11 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 2,334 | 28.12 | 65,632 |
| 2024-12-11 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Sale | 1,455 | 28.12 | 40,914 |
| 2024-12-09 | Kersten Dirk | Sale | 34,437 | 29.18 | 1,004,871 |
| 2024-12-06 | Kersten Dirk | Sale | 101,675 | 29.34 | 2,983,144 |
| 2024-12-05 | Kersten Dirk | Sale | 3,806 | 29.05 | 110,564 |
| 2024-12-04 | Kersten Dirk | Sale | 135,039 | 29.39 | 3,968,796 |
| 2024-12-03 | Kersten Dirk | Sale | 29,732 | 29.05 | 863,714 |
| 2024-12-02 | Kersten Dirk | Sale | 81,201 | 30.02 | 2,437,248 |
| 2024-11-18 | Incerti Carlo | Sale | 16,500 | 28.73 | 474,045 |
| 2024-11-18 | Incerti Carlo | Option Ex | 16,500 | 8.69 | 143,385 |
| 2024-11-14 | Kersten Dirk | Sale | 8,929 | 32.82 | 293,049 |
| 2024-11-14 | Rhodes Jason P | Sale | 782 | 33.10 | 25,884 |
| 2024-11-13 | Kersten Dirk | Sale | 10,803 | 35.24 | 380,697 |
| 2024-10-21 | Kersten Dirk | Sale | 121 | 35.06 | 4,242 |
| 2024-10-18 | Kersten Dirk | Sale | 13,414 | 35.16 | 471,636 |
| 2024-10-17 | Kersten Dirk | Sale | 13,013 | 35.17 | 457,667 |
| 2024-10-16 | Kersten Dirk | Sale | 23,671 | 35.35 | 836,769 |
| 2024-10-03 | Kersten Dirk | Sale | 5,441 | 35.13 | 191,142 |
| 2024-10-02 | Kersten Dirk | Sale | 21,518 | 35.38 | 761,306 |
| 2024-10-01 | Kersten Dirk | Sale | 8,423 | 35.16 | 296,152 |
| 2024-09-23 | Kersten Dirk | Sale | 40,831 | 35.76 | 1,460,116 |
| 2024-09-20 | Kersten Dirk | Sale | 79,411 | 36.73 | 2,916,766 |
| 2024-09-19 | Kersten Dirk | Sale | 78,739 | 36.08 | 2,840,509 |
| 2024-09-18 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 2,339 | 34.55 | 80,812 |
| 2024-09-18 | Kersten Dirk | Sale | 1,554 | 35.03 | 54,436 |
| 2024-09-18 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Sale | 1,390 | 34.55 | 48,024 |
| 2024-09-18 | High Susanna Gatti (Chief Operating Officer) | Sale | 8,976 | 34.41 | 308,864 |
| 2024-09-17 | Kersten Dirk | Sale | 3,272 | 35.13 | 114,945 |
| 2024-09-16 | Kersten Dirk | Sale | 1,320 | 35.04 | 46,252 |
| 2024-09-11 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 2,161 | 31.89 | 68,914 |
| 2024-09-11 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Sale | 1,468 | 31.89 | 46,814 |
| 2024-09-11 | High Susanna Gatti (Chief Operating Officer) | Sale | 5,270 | 31.89 | 168,060 |
| 2024-09-06 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Sale | 126,074 | 32.38 | 4,082,906 |
| 2024-09-06 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Option Ex | 116,478 | 10.48 | 1,221,038 |
| 2024-09-05 | Kersten Dirk | Sale | 1,577 | 35.03 | 55,242 |
| 2024-09-04 | Cox John (CEO & President) | Buy | 32,000 | 32.83 | 1,050,560 |
| 2024-08-30 | Kersten Dirk | Sale | 31,300 | 45.75 | 1,431,975 |
| 2024-08-29 | Kersten Dirk | Sale | 56,408 | 45.50 | 2,566,564 |
| 2024-08-28 | Kersten Dirk | Sale | 77,853 | 44.67 | 3,478,082 |
| 2024-08-27 | Kersten Dirk | Sale | 65,403 | 44.28 | 2,896,044 |
| 2024-08-26 | Kersten Dirk | Sale | 89,497 | 45.51 | 4,073,008 |
| 2024-08-23 | Kersten Dirk | Sale | 85,088 | 46.09 | 3,922,131 |
| 2024-08-22 | Kersten Dirk | Sale | 95,321 | 46.40 | 4,422,417 |
| 2024-08-19 | Farwell Wildon (Chief Medical Officer) | Sale | 2,321 | 45.51 | 105,617 |
| 2024-08-19 | Mcneill Jonathan (Chief Business Officer) | Sale | 2,705 | 45.51 | 123,091 |
| 2024-08-19 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 2,636 | 45.51 | 119,951 |
| 2024-08-19 | Kersten Dirk | Sale | 126,032 | 45.90 | 5,784,868 |
| 2024-08-19 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Sale | 2,752 | 45.51 | 125,229 |
| 2024-08-19 | High Susanna Gatti (Chief Operating Officer) | Sale | 2,910 | 45.51 | 132,419 |
| 2024-08-16 | Kersten Dirk | Sale | 122,643 | 45.35 | 5,562,227 |
| 2024-08-15 | Kersten Dirk | Sale | 180,891 | 45.46 | 8,223,304 |
| 2024-08-14 | Kersten Dirk | Sale | 100,650 | 43.67 | 4,395,385 |
| 2024-08-13 | Kersten Dirk | Sale | 133,985 | 42.81 | 5,735,897 |
| 2024-08-12 | Kersten Dirk | Sale | 78,492 | 43.08 | 3,381,435 |
| 2024-06-24 | High Susanna Gatti (Chief Operating Officer) | Sale | 10,163 | 35.33 | 359,058 |
| 2024-06-24 | High Susanna Gatti (Chief Operating Officer) | Option Ex | 10,163 | 5.54 | 56,303 |
| 2024-06-21 | High Susanna Gatti (Chief Operating Officer) | Sale | 29,787 | 35.01 | 1,042,842 |
| 2024-06-21 | High Susanna Gatti (Chief Operating Officer) | Option Ex | 29,787 | 5.54 | 165,019 |
| 2024-06-12 | High Susanna Gatti (Chief Operating Officer) | Sale | 40,000 | 33.44 | 1,337,400 |
| 2024-06-12 | High Susanna Gatti (Chief Operating Officer) | Option Ex | 40,000 | 5.54 | 221,600 |
| 2024-06-11 | Farwell Wildon (Chief Medical Officer) | Sale | 2,636 | 31.27 | 82,427 |
| 2024-06-11 | Mcneill Jonathan (Chief Business Officer) | Sale | 1,823 | 31.34 | 57,132 |
| 2024-06-11 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 2,136 | 31.34 | 66,942 |
| 2024-06-11 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Sale | 1,331 | 31.34 | 41,713 |
| 2024-06-11 | High Susanna Gatti (Chief Operating Officer) | Sale | 5,270 | 31.23 | 164,582 |
| 2024-06-10 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Sale | 1,590 | 30.23 | 48,065 |
| 2024-06-10 | High Susanna Gatti (Chief Operating Officer) | Sale | 80,000 | 30.24 | 2,419,200 |
| 2024-06-10 | High Susanna Gatti (Chief Operating Officer) | Option Ex | 80,000 | 5.54 | 443,200 |
| 2024-05-20 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 30,426 | 33.36 | 1,015,011 |
| 2024-05-20 | Beskrovnaya Oxana (Chief Scientific Officer) | Option Ex | 30,426 | 1.03 | 31,338 |
| 2024-05-16 | Farwell Wildon (Chief Medical Officer) | Sale | 2,381 | 28.39 | 67,608 |
| 2024-05-16 | Mcneill Jonathan (Chief Business Officer) | Sale | 2,774 | 28.39 | 78,767 |
| 2024-05-16 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 2,705 | 28.39 | 76,808 |
| 2024-05-16 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Sale | 2,588 | 28.39 | 73,486 |
| 2024-05-16 | High Susanna Gatti (Chief Operating Officer) | Sale | 2,738 | 28.39 | 77,745 |
| 2024-03-12 | Farwell Wildon (Chief Medical Officer) | Sale | 1,030 | 25.58 | 26,347 |
| 2024-03-11 | Farwell Wildon (Chief Medical Officer) | Sale | 1,585 | 25.70 | 40,734 |
| 2024-03-11 | Mcneill Jonathan (Chief Business Officer) | Sale | 19,601 | 25.59 | 501,687 |
| 2024-03-11 | Mcneill Jonathan (Chief Business Officer) | Option Ex | 17,825 | 5.54 | 98,750 |
| 2024-03-11 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 2,081 | 25.70 | 53,481 |
| 2024-03-11 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Sale | 2,672 | 25.34 | 67,721 |
| 2024-03-11 | High Susanna Gatti (Chief Operating Officer) | Sale | 2,292 | 25.70 | 58,904 |
| 2024-03-11 | Brumm Joshua T (CEO & President) | Sale | 66,387 | 25.89 | 1,718,958 |
| 2024-03-11 | Brumm Joshua T (CEO & President) | Option Ex | 50,000 | 5.54 | 277,000 |
| 2024-03-08 | Mcneill Jonathan (Chief Business Officer) | Sale | 90,000 | 26.50 | 2,384,730 |
| 2024-03-08 | Mcneill Jonathan (Chief Business Officer) | Option Ex | 90,000 | 5.54 | 498,600 |
| 2024-03-08 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Sale | 86,252 | 26.45 | 2,281,624 |
| 2024-03-08 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Option Ex | 86,252 | 5.54 | 477,836 |
| 2024-03-08 | High Susanna Gatti (Chief Operating Officer) | Sale | 27,199 | 27.04 | 735,324 |
| 2024-03-08 | Brumm Joshua T (CEO & President) | Sale | 363,343 | 26.47 | 9,616,599 |
| 2024-03-08 | Brumm Joshua T (CEO & President) | Option Ex | 363,343 | 5.54 | 2,012,920 |
| 2024-03-07 | Farwell Wildon (Chief Medical Officer) | Sale | 9,921 | 26.00 | 257,946 |
| 2024-03-07 | Mcneill Jonathan (Chief Business Officer) | Sale | 2,434 | 25.85 | 62,918 |
| 2024-03-07 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 2,373 | 25.85 | 61,342 |
| 2024-03-07 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Sale | 2,273 | 25.85 | 58,757 |
| 2024-03-07 | High Susanna Gatti (Chief Operating Officer) | Sale | 1,591 | 25.85 | 41,127 |
| 2024-03-07 | Brumm Joshua T (CEO & President) | Sale | 9,086 | 25.85 | 234,873 |
| 2024-03-01 | Atlas Venture Associates Opportunity Ii, Llc | Sale | 46,534 | 30.05 | 1,398,346 |
| 2024-03-01 | Mcneill Jonathan (Chief Business Officer) | Sale | 24,260 | 29.00 | 703,612 |
| 2024-03-01 | Mcneill Jonathan (Chief Business Officer) | Option Ex | 24,260 | .73 | 17,709 |
| 2024-03-01 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Sale | 9,311 | 28.43 | 264,758 |
| 2024-03-01 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Option Ex | 9,311 | 1.03 | 9,590 |
| 2024-03-01 | Rhodes Jason P | Sale | 46,534 | 30.05 | 1,398,346 |
| 2024-03-01 | Brumm Joshua T (CEO & President) | Sale | 94,480 | 29.06 | 2,745,588 |
| 2024-03-01 | Brumm Joshua T (CEO & President) | Option Ex | 94,480 | 5.54 | 523,419 |
| 2024-02-29 | Mcneill Jonathan (Chief Business Officer) | Sale | 4,268 | 27.50 | 117,370 |
| 2024-02-29 | Mcneill Jonathan (Chief Business Officer) | Option Ex | 4,268 | .73 | 3,115 |
| 2024-02-29 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Sale | 3,429 | 27.50 | 94,297 |
| 2024-02-29 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Option Ex | 3,429 | 1.03 | 3,531 |
| 2024-02-29 | Brumm Joshua T (CEO & President) | Sale | 5,520 | 27.50 | 151,800 |
| 2024-02-29 | Brumm Joshua T (CEO & President) | Option Ex | 5,520 | 5.54 | 30,580 |
| 2024-02-28 | Atlas Venture Associates Opportunity Ii, Llc | Sale | 190,920 | 25.04 | 4,780,636 |
| 2024-02-28 | Rhodes Jason P | Sale | 190,920 | 25.04 | 4,780,636 |
| 2024-02-27 | Atlas Venture Associates Opportunity Ii, Llc | Sale | 368,699 | 24.53 | 9,044,186 |
| 2024-02-27 | Rhodes Jason P | Sale | 368,699 | 24.53 | 9,044,186 |
| 2024-02-26 | Atlas Venture Associates Opportunity Ii, Llc | Sale | 248,219 | 23.79 | 5,903,888 |
| 2024-02-26 | Rhodes Jason P | Sale | 248,219 | 23.79 | 5,903,888 |
| 2024-02-23 | Atlas Venture Associates Opportunity Ii, Llc | Sale | 196,928 | 22.70 | 4,470,265 |
| 2024-02-23 | Rhodes Jason P | Sale | 196,928 | 22.70 | 4,470,265 |
| 2024-02-22 | Atlas Venture Associates Opportunity Ii, Llc | Sale | 119,360 | 22.66 | 2,704,697 |
| 2024-02-22 | Rhodes Jason P | Sale | 119,360 | 22.66 | 2,704,697 |
| 2024-02-21 | Atlas Venture Associates Opportunity Ii, Llc | Sale | 184,501 | 22.79 | 4,204,777 |
| 2024-02-21 | Rhodes Jason P | Sale | 184,501 | 22.79 | 4,204,777 |
| 2024-02-20 | Atlas Venture Associates Xi, Llc | Sale | 169,539 | 23.05 | 3,908,721 |
| 2024-02-20 | Rhodes Jason P | Sale | 169,539 | 23.05 | 3,908,721 |
| 2024-02-16 | Atlas Venture Associates Xi, Llc | Sale | 162,707 | 23.14 | 3,765,039 |
| 2024-02-16 | Rhodes Jason P | Sale | 162,707 | 23.14 | 3,765,039 |
| 2024-02-15 | Atlas Venture Associates Xi, Llc | Sale | 177,906 | 24.16 | 4,299,098 |
| 2024-02-15 | Rhodes Jason P | Sale | 177,906 | 24.16 | 4,299,098 |
| 2024-02-12 | Farwell Wildon (Chief Medical Officer) | Sale | 5,493 | 25.07 | 137,709 |
| 2024-01-26 | Farwell Wildon (Chief Medical Officer) | Sale | 100 | 25.00 | 2,500 |
| 2024-01-26 | Mcneill Jonathan (Chief Business Officer) | Sale | 20,000 | 24.83 | 496,599 |
| 2024-01-26 | Mcneill Jonathan (Chief Business Officer) | Option Ex | 20,000 | .73 | 14,600 |
| 2024-01-26 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Sale | 13,000 | 24.34 | 316,420 |
| 2024-01-26 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Option Ex | 13,000 | 1.03 | 13,390 |
| 2024-01-09 | Kersten Dirk | Buy | 1,714,285 | 17.50 | 29,999,987 |
| 2024-01-04 | Mcneill Jonathan (Chief Business Officer) | Sale | 2,009 | 18.04 | 36,242 |
| 2024-01-04 | Mcneill Jonathan (Chief Business Officer) | Option Ex | 2,009 | .73 | 1,466 |
| 2024-01-04 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 42,453 | 18.13 | 769,672 |
| 2024-01-04 | Beskrovnaya Oxana (Chief Scientific Officer) | Option Ex | 22,674 | 1.03 | 23,354 |
| 2024-01-04 | Brumm Joshua T (CEO & President) | Sale | 218,536 | 18.73 | 4,092,086 |
| 2024-01-04 | Brumm Joshua T (CEO & President) | Option Ex | 218,536 | 3.29 | 717,890 |
| 2024-01-03 | Mcneill Jonathan (Chief Business Officer) | Sale | 17,991 | 18.68 | 336,161 |
| 2024-01-03 | Mcneill Jonathan (Chief Business Officer) | Option Ex | 17,991 | .73 | 13,133 |
| 2024-01-03 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 45,326 | 19.30 | 874,655 |
| 2024-01-03 | Beskrovnaya Oxana (Chief Scientific Officer) | Option Ex | 45,326 | 1.03 | 46,685 |
| 2024-01-03 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Sale | 13,000 | 18.81 | 244,529 |
| 2024-01-03 | Scalzo Richard William (SVP, Head of Finance & Admin.) | Option Ex | 13,000 | 1.03 | 13,390 |
| 2024-01-03 | Brumm Joshua T (CEO & President) | Sale | 51,183 | 19.29 | 987,320 |
| 2024-01-03 | Brumm Joshua T (CEO & President) | Option Ex | 51,183 | 1.03 | 52,718 |
| 2024-01-02 | Mcneill Jonathan (Chief Business Officer) | Sale | 11,900 | 13.10 | 155,890 |
| 2023-12-14 | Scalzo Richard William (See Remarks) | Sale | 2,376 | 12.02 | 28,559 |
| 2023-12-12 | Farwell Wildon (Chief Medical Officer) | Sale | 978 | 10.55 | 10,317 |
| 2023-12-11 | Farwell Wildon (Chief Medical Officer) | Sale | 1,688 | 10.72 | 18,095 |
| 2023-12-11 | Mcneill Jonathan (Chief Business Officer) | Sale | 1,245 | 10.72 | 13,346 |
| 2023-12-11 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 1,467 | 10.72 | 15,726 |
| 2023-12-11 | Scalzo Richard William (See Remarks) | Sale | 1,380 | 10.72 | 14,793 |
| 2023-12-11 | High Susanna Gatti (Chief Operating Officer) | Sale | 1,616 | 10.72 | 17,323 |
| 2023-12-11 | Brumm Joshua T (See Remarks) | Sale | 7,585 | 10.72 | 81,311 |
| 2023-12-06 | Scalzo Richard William (See Remarks) | Sale | 1,872 | 12.01 | 22,482 |
| 2023-12-04 | Scalzo Richard William (See Remarks) | Sale | 681 | 12.01 | 8,178 |
| 2023-11-02 | High Susanna Gatti (Chief Operating Officer) | Sale | 9,939 | 7.40 | 73,548 |
| 2023-09-18 | Mcneill Jonathan (Chief Business Officer) | Sale | 1,261 | 9.41 | 11,866 |
| 2023-09-18 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 1,436 | 9.41 | 13,512 |
| 2023-09-18 | Scalzo Richard William (See Remarks) | Sale | 1,290 | 9.41 | 12,138 |
| 2023-09-18 | High Susanna Gatti (Chief Operating Officer) | Sale | 2,672 | 9.41 | 25,143 |
| 2023-09-18 | Brumm Joshua T (See Remarks) | Sale | 12,032 | 9.41 | 113,221 |
| 2023-09-12 | Farwell Wildon (Chief Medical Officer) | Sale | 1,707 | 10.41 | 17,769 |
| 2023-09-12 | Mcneill Jonathan (Chief Business Officer) | Sale | 1,266 | 10.41 | 13,179 |
| 2023-09-12 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 1,484 | 10.41 | 15,448 |
| 2023-09-12 | Scalzo Richard William (See Remarks) | Sale | 1,397 | 10.41 | 14,542 |
| 2023-09-12 | High Susanna Gatti (Chief Operating Officer) | Sale | 1,635 | 10.41 | 17,020 |
| 2023-09-12 | Brumm Joshua T (See Remarks) | Sale | 7,672 | 10.41 | 79,865 |
| 2023-06-15 | Scalzo Richard William (See Remarks) | Sale | 10,000 | 12.03 | 120,300 |
| 2023-06-13 | Farwell Wildon (Chief Medical Officer) | Sale | 1,698 | 12.43 | 21,106 |
| 2023-06-13 | Mcneill Jonathan (See Remarks) | Sale | 1,259 | 12.43 | 15,649 |
| 2023-06-13 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 1,475 | 12.43 | 18,334 |
| 2023-06-13 | Scalzo Richard William (See Remarks) | Sale | 41,390 | 12.66 | 523,997 |
| 2023-06-13 | Scalzo Richard William (See Remarks) | Option Ex | 40,000 | 1.03 | 41,200 |
| 2023-06-13 | High Susanna Gatti (Chief Operating Officer) | Sale | 1,625 | 12.43 | 20,198 |
| 2023-06-12 | Mcneill Jonathan (See Remarks) | Sale | 1,000 | 13.00 | 13,000 |
| 2023-06-12 | Brumm Joshua T (See Remarks) | Sale | 187,748 | 12.61 | 2,367,502 |
| 2023-06-12 | Brumm Joshua T (See Remarks) | Option Ex | 171,360 | 1.03 | 176,500 |
| 2023-06-09 | Brumm Joshua T (See Remarks) | Sale | 76,582 | 13.34 | 1,021,603 |
| 2023-06-09 | Brumm Joshua T (See Remarks) | Option Ex | 76,582 | 1.03 | 78,879 |
| 2023-06-08 | Brumm Joshua T (See Remarks) | Sale | 61,000 | 13.31 | 811,910 |
| 2023-06-08 | Brumm Joshua T (See Remarks) | Option Ex | 30,088 | 1.03 | 30,990 |
| 2023-03-14 | Farwell Wildon (Chief Medical Officer) | Sale | 7,441 | 13.33 | 99,188 |
| 2023-03-14 | Mcneill Jonathan (See Remarks) | Sale | 1,209 | 13.33 | 16,115 |
| 2023-03-14 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 1,416 | 13.33 | 18,875 |
| 2023-03-14 | Scalzo Richard William (See Remarks) | Sale | 1,311 | 13.33 | 17,475 |
| 2023-03-14 | High Susanna Gatti (Chief Operating Officer) | Sale | 1,559 | 13.33 | 20,781 |
| 2023-03-14 | Brumm Joshua T (See Remarks) | Sale | 7,318 | 13.33 | 97,548 |
| 2023-03-13 | Mcneill Jonathan (See Remarks) | Sale | 1,000 | 13.00 | 13,000 |
| 2023-01-18 | Mcneill Jonathan (See Remarks) | Sale | 10,000 | 14.03 | 140,300 |
| 2023-01-18 | Mcneill Jonathan (See Remarks) | Option Ex | 10,000 | .73 | 7,300 |
| 2022-12-12 | Atlas Venture Associates Opportunity Ii, Llc (10% Owner) | Buy | 934,581 | 10.70 | 10,000,016 |
| 2022-12-12 | Rhodes Jason P (Director) | Buy | 934,581 | 10.70 | 10,000,016 |
| 2022-10-10 | Brumm Joshua T (See Remarks) | Sale | 195,800 | 12.46 | 2,439,668 |
| 2022-10-10 | Brumm Joshua T (See Remarks) | Option Ex | 195,800 | 1.03 | 201,674 |
| 2022-10-07 | Brumm Joshua T (See Remarks) | Sale | 14,200 | 13.37 | 189,854 |
| 2022-10-07 | Brumm Joshua T (See Remarks) | Option Ex | 14,200 | 1.03 | 14,626 |
| 2022-03-11 | Farwell Wildon (Chief Medical Officer) | Sale | 640 | 8.73 | 5,587 |
| 2022-03-11 | Mcneill Jonathan (See Remarks) | Sale | 481 | 8.73 | 4,199 |
| 2022-03-11 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 693 | 8.73 | 6,049 |
| 2022-03-11 | Scalzo Richard William (See Remarks) | Sale | 308 | 8.73 | 2,688 |
| 2022-03-11 | High Susanna Gatti (Chief Operating Officer) | Sale | 765 | 8.73 | 6,678 |
| 2022-03-11 | Brumm Joshua T (See Remarks) | Sale | 3,384 | 8.73 | 29,542 |
| 2022-03-02 | Farwell Wildon (Chief Medical Officer) | Sale | 5,617 | 8.56 | 48,081 |
| 2021-09-23 | High Susanna Gatti (Chief Operating Officer) | Sale | 2,451 | 17.22 | 42,206 |
| 2021-09-21 | Mcneill Jonathan (See Remarks) | Sale | 729 | 16.11 | 11,744 |
| 2021-09-21 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 827 | 16.11 | 13,322 |
| 2021-09-21 | Scalzo Richard William (See Remarks) | Sale | 492 | 16.11 | 7,926 |
| 2021-09-21 | Brumm Joshua T (See Remarks) | Sale | 4,584 | 16.11 | 73,848 |
| 2021-09-20 | Mcneill Jonathan (See Remarks) | Sale | 545 | 15.61 | 8,507 |
| 2021-09-20 | Beskrovnaya Oxana (Chief Scientific Officer) | Sale | 617 | 15.61 | 9,631 |
| 2021-09-20 | Scalzo Richard William (See Remarks) | Sale | 367 | 15.61 | 5,728 |
| 2021-09-20 | Brumm Joshua T (See Remarks) | Sale | 3,425 | 15.61 | 53,464 |
| 2020-09-21 | Logos Global Management Lp (10% Owner) | Buy | 700,000 | 19.00 | 13,300,000 |
| 2020-09-21 | Vida Ventures Ii-a, Llc (10% Owner) | Buy | 815,000 | 19.00 | 15,485,000 |
| 2020-09-21 | Shah Rajeev M. | Buy | 660,000 | 19.00 | 12,540,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of DYN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Dyne Therapeutics, Inc. (symbol DYN, CIK number 1818794) see the Securities and Exchange Commission (SEC) website.